Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73afc696dd3f4cdb9e9b5c42aebac4fb |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
filingDate |
2019-06-28^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2021-05-18^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7c4777f65dbea549c5f3141dfc730ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c34f394390b918335dcb648ce2605b2 |
publicationDate |
2021-05-18^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-11007139-B2 |
titleOfInvention |
Risperidone or paliperidone implant formulation |
abstract |
The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11752093-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022192972-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023046731-A1 |
priorityDate |
2010-05-31^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |